Please assess the completion status of the following clinical trial:

Trial Title: Remission and Joint Damage Progression in Early Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of rheumatoid arthritis (RA) \<=2 years; MTX naive or \<=10 mg/wk for \<=3 weeks. No dose within 3 months prior to informed consent.~* C-Reactive Protein (CRP) \>= 4.5 mg/L (after amendment)~* Rheumatoid factor or anti-cyclic citrullinated peptide antibody (anti-CCP) positive~* Tender joints \>=12 and swollen joints \>=10~Exclusion Criteria:~* Women and men who are not willing to use birth control~* Diagnosed with other rheumatic disease~* History of cancer within 5 years~* Active tuberculosis~* Treatment with another investigation drug within 28 days~* Active bacterial or viral infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ABA + MTX (Type: ACTIVE_COMPARATOR): abatacept 10 mg/kg intravenous (IV) + methotrexate
- Placebo (PLA) + MTX (Type: ACTIVE_COMPARATOR): placebo IV + methotrexate

Based on this trial design, predict the completion outcome and termination type (if applicable).